（2025 年 10 月修订） 贵州益佰制药股份有限公司 独立董事年度报告工作制度 第七条 独立董事应对公司年报编制过程中获取的信息保密，关注和严防泄漏内 幕信息、进行内幕交易等违规违法行为的发生。 第一条 为进一步完善公司治理机制，夯实信息披露编制工作基础，充分发挥公 司独立董事在年度报告编制工作中的作用，根据中国证监会的相关要求及《上市公司 独立董事管理办法》《公司章程》的有关规定，特制定本制度。 第二条 独立董事应在公司年度报告编制和披露过程中切实履行独立董事的职责 和义务，勤勉尽责。 第三条 在年度报告编制期间，公司管理层应向独立董事全面汇报公司本年度的 经营情况和重大事项的进展情况，并安排每位独立董事进行实地考察。 第四条 在为公司提供年度报告审计的注册会计师（以下简称"年审注册会计师"） 进场审计前，公司财务负责人应向每位独立董事提交本年度审计工作安排的书面文件 及其他相关资料。 第五条 公司应在年审注册会计师出具初步审计意见后和召开董事会会议审议年 度报告前，至少安排一次每位独立董事与年审注册会计师的沟通，沟通审计过程中发 现的问题。独立董事应履行与年审注册会计师沟通的职责。 第六条 在履行上述 ...

贵州益佰制药股份有限公司 2025 年第三季度报告 证券代码：600594 证券简称：益佰制药 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 贵州益佰制药股份有限公司2025 年第三季度报告 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一）主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 比上年同 | 年初至报告期末 | 末比上年同期 | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 453,580,934.13 | -16.87 | 1,446,704 ...

益佰制药公告，第三季度营收为4.54亿元，同比下降16.87%；净利润亏损6666.06万元。前三季度营收 为14.47亿元，同比下降15.59%；净利润亏损8656.26万元。 ...

Core Points - The company announced the approval of a proposal to sell its stock assets during the 11th Board Meeting and the first extraordinary shareholders' meeting in September 2025 [1] - The aim of the asset sale is to optimize the company's asset structure, focus on its main business, and release the value of certain assets [1] - The management is authorized to sell a total of 8,685,953 shares of Guizhou Yibai Pharmaceutical Co., Ltd., 970,605 shares of Aoyuan Optical Technology Co., Ltd., 7,716 shares of China Ping An Insurance (Group) Co., Ltd., and 4,712,205 shares of Hunan Erkang Pharmaceutical Co., Ltd. through centralized bidding, block trading, or a combination of both by December 31, 2025 [1] - The company has completed the sale of its holdings in Yibai Pharmaceutical, Aoyuan, Ping An, and Erkang Pharmaceutical [1]

Group 1 - The Guizhou provincial government organized a delegation of health and pharmaceutical companies to participate in the 30th Macao International Trade and Investment Fair (MIF) to enhance economic cooperation with Portuguese-speaking countries and connect with the Guangdong-Hong Kong-Macao Greater Bay Area market [2] - The participating companies include Guizhou Yibai Health Pharmaceutical, Guizhou Bailing Group, and several others focusing on ethnic medicine innovation and modern biotechnology [2] - The event showcased Guizhou's unique health products, emphasizing the integration of traditional wisdom and modern technology in the pharmaceutical sector [4] Group 2 - Key products highlighted include classic medicines represented by Miao medicine, authentic medicinal materials like Tianma and Dendrobium, and functional foods derived from Huangjing and prickly pear, reflecting Guizhou's rich natural resources [4] - Guizhou Jinchaolan Biotechnology Co., Ltd. secured orders worth 20 million RMB with local companies in Macao, while Guizhou Yibai Health Pharmaceutical reached a cooperation agreement for the registration of functional foods in Brazil [4] - The Guizhou provincial government aims to leverage the MIF as an international platform to seek more global cooperation opportunities and expand overseas marketing channels [4]

Market Overview - On October 17, the traditional Chinese medicine sector declined by 0.99%, with Tianmu Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Notable gainers in the traditional Chinese medicine sector included: - Weikang Pharmaceutical: closed at 23.39, up 3.54% with a trading volume of 84,100 shares and a turnover of 26.66 million [1] - Enwei Pharmaceutical: closed at 31.40, up 2.45% with a trading volume of 24,700 shares and a turnover of 78.62 million [1] - Zhongsheng Pharmaceutical: closed at 17.45, up 2.11% with a trading volume of 706,300 shares and a turnover of 1.244 billion [1] - Major decliners included: - Tianmu Pharmaceutical: closed at 18.40, down 5.30% with a trading volume of 120,100 shares and a turnover of 22 million [2] - Jilin Aodong: closed at 20.23, down 3.39% with a trading volume of 226,500 shares and a turnover of 465 million [2] Capital Flow - The traditional Chinese medicine sector experienced a net outflow of 736 million from institutional investors, while retail investors saw a net inflow of 582 million [2][3] - Key stocks with significant capital flow included: - Zhongsheng Pharmaceutical: net inflow of 72.58 million from institutional investors, but a net outflow of 131 million from retail investors [3] - Tianmu Pharmaceutical: net inflow of 19.99 million from institutional investors, with net outflows from both retail and speculative investors [3]

Core Viewpoint - Yibai Pharmaceutical announced that its controlling shareholder, Ms. Dou Qiling, has recently lifted the pledge on a portion of her shares in the company, totaling 41,891,738 shares [2] Group 1 - The number of shares released from pledge is 41,891,738 [2]

证券代码：600594 证券简称：益佰制药 公告编号：2025-030 贵州益佰制药股份有限公司 关于控股股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 控股股东窦啟玲女士持有贵州益佰制药股份有限公司（以下简称"公司"） 股份数量 185,457,636 股，占公司总股本的 23.42%。本次解除质押股份后，控 股股东窦啟玲女士持有公司股份累计质押数量为 22,668,262 股，占其所持公司 股份的 12.22%，占公司总股本的 2.86%。 本次解除质押股份后，控股股东窦啟玲女士及其一致行动人窦雅琪女士累 计质押股份数量为 22,668,262 股，占窦啟玲女士及其一致行动人窦雅琪女士合 计所持公司股份的 12.21%，占公司总股本的 2.86%。 近日，公司获悉控股股东窦啟玲女士将所持有的本公司部分股份办理了股票 解除质押手续，具体情况如下： 一、本次股份解除质押情况 单位：股 | 股东名称 | 窦啟玲 | | --- | --- | | 本次解除质押股数 | 41,891,7 ...

南财智讯10月15日电，益佰制药公告，控股股东窦啟玲解除质押4189.17万股，占其所持股份的 22.59%，占公司总股本的5.29%。解除质押后，窦啟玲累计质押股份2266.83万股，占其所持股份的 12.22%，占公司总股本的2.86%。窦啟玲及其一致行动人窦雅琪合计质押股份2266.83万股，占其合计所 持股份的12.21%，占公司总股本的2.86%。本次解除质押的股份如后续用于其他质押业务，公司将根据 相关法律法规要求及时履行信息披露义务。 ...

Group 1 - The core point of the news is that Yibai Pharmaceutical (600594) has seen a net financing purchase of 223.49 million yuan on September 23, 2025, with a total financing balance of 2.76 billion yuan, indicating a positive trend in investor sentiment towards the stock [1][2][3] - Over the past three trading days, the cumulative net purchase has reached 647.88 million yuan, reflecting increasing investor confidence [1] - The financing balance has increased by 0.82% compared to the previous day, showing a consistent upward trend in financing activities [3] Group 2 - The financing net purchases for the last few trading days are as follows: 223.49 million yuan on September 23, 126.97 million yuan on September 22, and 297.42 million yuan on September 19, indicating fluctuating but generally positive investor activity [2][3] - The financing balance as a percentage of the circulating market value has risen from 7.88% on September 18 to 8.57% on September 23, suggesting a growing interest in the stock relative to its market size [2] - There were no short selling transactions on the day of the report, indicating a lack of bearish sentiment in the market for this stock [1]